259 related articles for article (PubMed ID: 9749582)
1. Glial cells and inflammation in Parkinson's disease: a role in neurodegeneration?
Hirsch EC; Hunot S; Damier P; Faucheux B
Ann Neurol; 1998 Sep; 44(3 Suppl 1):S115-20. PubMed ID: 9749582
[TBL] [Abstract][Full Text] [Related]
2. The role of glial reaction and inflammation in Parkinson's disease.
Hirsch EC; Breidert T; Rousselet E; Hunot S; Hartmann A; Michel PP
Ann N Y Acad Sci; 2003 Jun; 991():214-28. PubMed ID: 12846989
[TBL] [Abstract][Full Text] [Related]
3. Microglial activation-mediated delayed and progressive degeneration of rat nigral dopaminergic neurons: relevance to Parkinson's disease.
Gao HM; Jiang J; Wilson B; Zhang W; Hong JS; Liu B
J Neurochem; 2002 Jun; 81(6):1285-97. PubMed ID: 12068076
[TBL] [Abstract][Full Text] [Related]
4. Glial cell participation in the degeneration of dopaminergic neurons in Parkinson's disease.
Hirsch EC; Hunot S; Damier P; Brugg B; Faucheux BA; Michel PP; Ruberg M; Muriel MP; Mouatt-Prigent A; Agid Y
Adv Neurol; 1999; 80():9-18. PubMed ID: 10410697
[No Abstract] [Full Text] [Related]
5. Estrogen, neuroinflammation and neuroprotection in Parkinson's disease: glia dictates resistance versus vulnerability to neurodegeneration.
Morale MC; Serra PA; L'episcopo F; Tirolo C; Caniglia S; Testa N; Gennuso F; Giaquinta G; Rocchitta G; Desole MS; Miele E; Marchetti B
Neuroscience; 2006; 138(3):869-78. PubMed ID: 16337092
[TBL] [Abstract][Full Text] [Related]
6. Neuroinflammation in Parkinson's disease: a target for neuroprotection?
Hirsch EC; Hunot S
Lancet Neurol; 2009 Apr; 8(4):382-97. PubMed ID: 19296921
[TBL] [Abstract][Full Text] [Related]
7. Does monoamine oxidase type B play a role in dopaminergic nerve cell death in Parkinson's disease?
Damier P; Kastner A; Agid Y; Hirsch EC
Neurology; 1996 May; 46(5):1262-9. PubMed ID: 8628464
[TBL] [Abstract][Full Text] [Related]
8. Dopamine-dependent neurotoxicity of alpha-synuclein: a mechanism for selective neurodegeneration in Parkinson disease.
Xu J; Kao SY; Lee FJ; Song W; Jin LW; Yankner BA
Nat Med; 2002 Jun; 8(6):600-6. PubMed ID: 12042811
[TBL] [Abstract][Full Text] [Related]
9. Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease.
Novikova L; Garris BL; Garris DR; Lau YS
Neuroscience; 2006 Jun; 140(1):67-76. PubMed ID: 16533572
[TBL] [Abstract][Full Text] [Related]
10. The role of glial cells in Parkinson's disease.
Vila M; Jackson-Lewis V; Guégan C; Wu DC; Teismann P; Choi DK; Tieu K; Przedborski S
Curr Opin Neurol; 2001 Aug; 14(4):483-9. PubMed ID: 11470965
[TBL] [Abstract][Full Text] [Related]
11. Inflammatory process as a determinant factor for the degeneration of substantia nigra dopaminergic neurons.
Herrera AJ; Tomás-Camardiel M; Venero JL; Cano J; Machado A
J Neural Transm (Vienna); 2005 Jan; 112(1):111-9. PubMed ID: 15599609
[TBL] [Abstract][Full Text] [Related]
12. The role of astroglia on the survival of dopamine neurons.
Mena MA; de Bernardo S; Casarejos MJ; Canals S; Rodríguez-Martín E
Mol Neurobiol; 2002 Jun; 25(3):245-63. PubMed ID: 12109874
[TBL] [Abstract][Full Text] [Related]
13. Hormones are key actors in gene x environment interactions programming the vulnerability to Parkinson's disease: glia as a common final pathway.
Marchetti B; Serra PA; L'Episcopo F; Tirolo C; Caniglia S; Testa N; Cioni S; Gennuso F; Rocchitta G; Desole MS; Mazzarino MC; Miele E; Morale MC
Ann N Y Acad Sci; 2005 Dec; 1057():296-318. PubMed ID: 16399902
[TBL] [Abstract][Full Text] [Related]
14. Neuronal vulnerability in Parkinson's disease.
Hirsch EC; Faucheux B; Damier P; Mouatt-Prigent A; Agid Y
J Neural Transm Suppl; 1997; 50():79-88. PubMed ID: 9120427
[TBL] [Abstract][Full Text] [Related]
15. Nitric oxide synthase and neuronal vulnerability in Parkinson's disease.
Hunot S; Boissière F; Faucheux B; Brugg B; Mouatt-Prigent A; Agid Y; Hirsch EC
Neuroscience; 1996 May; 72(2):355-63. PubMed ID: 8737406
[TBL] [Abstract][Full Text] [Related]
16. Selective MAO-A and B inhibitors, radical scavengers and nitric oxide synthase inhibitors in Parkinson's disease.
Youdim MB; Lavie L
Life Sci; 1994; 55(25-26):2077-82. PubMed ID: 7527888
[TBL] [Abstract][Full Text] [Related]
17. Does oxidative stress participate in nerve cell death in Parkinson's disease?
Hirsch EC
Eur Neurol; 1993; 33 Suppl 1():52-9. PubMed ID: 8375433
[TBL] [Abstract][Full Text] [Related]
18. Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson's disease.
Zhang W; Wang T; Pei Z; Miller DS; Wu X; Block ML; Wilson B; Zhang W; Zhou Y; Hong JS; Zhang J
FASEB J; 2005 Apr; 19(6):533-42. PubMed ID: 15791003
[TBL] [Abstract][Full Text] [Related]
19. Neuroprotective effects of Astragaloside IV in 6-hydroxydopamine-treated primary nigral cell culture.
Chan WS; Durairajan SS; Lu JH; Wang Y; Xie LX; Kum WF; Koo I; Yung KK; Li M
Neurochem Int; 2009 Nov; 55(6):414-22. PubMed ID: 19409437
[TBL] [Abstract][Full Text] [Related]
20. Are Dopamine Oxidation Metabolites Involved in the Loss of Dopaminergic Neurons in the Nigrostriatal System in Parkinson's Disease?
Herrera A; Muñoz P; Steinbusch HWM; Segura-Aguilar J
ACS Chem Neurosci; 2017 Apr; 8(4):702-711. PubMed ID: 28233992
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
